Bahl & Gaynor’s Avanos Medical AVNS Stock Holding History

Bahl & Gaynor’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-9,258	Closed	-$421K	–	433
2014 Q4	$421K	Buy	+9,258	New	+$364K	0.01%	314

Other funds holding AVNS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RR Partners New York $929M AUM 110.28% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Bahl & Gaynor's AVNS Position: Q1 2015 in Review

Bahl & Gaynor sold out of Avanos Medical (AVNS) in Q1 2015, closing a stake of 9,258 shares — an estimated $421K sold.

Bahl & Gaynor first reported a position in AVNS in Q4 2014 and held it in 1 quarter. The position peaked at $421K in Q4 2014. 448 funds tracked by Wall St. Rank hold AVNS as of Q1 2015.

Bahl & Gaynor reported no remaining Avanos Medical position as of Q1 2015 after selling out during the quarter.
Bahl & Gaynor sold 9,258 Avanos Medical shares in Q1 2015, an estimated $421K.
Bahl & Gaynor first reported a position in Avanos Medical in Q4 2014 and held it in 1 quarter.
Bahl & Gaynor's Avanos Medical position peaked at $421K in Q4 2014.
448 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2015.

Based on Bahl & Gaynor's 13F filing for Q1 2015, filed 12 May 2015.